Tarsus Pharmaceuticals Inc Ordinary Shares TARS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $61.27
- Day Range
- $60.40–64.39
- 52-Week Range
- $38.52–85.00
- Bid/Ask
- $62.60 / $63.07
- Shares Outstanding
- 43.02M
- Market Cap
- $2.72B
- Volume/Avg
- 229,349 / 613,749
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.01%
Company Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 370
- Website
- https://www.tarsusrx.com
Valuation
|
Metric
|
TARS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.59 |
Price/Sales | 4.91 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TARS
|
|---|---|
Quick Ratio | 3.53 |
Current Ratio | 3.74 |
Interest Coverage | −6.27 |
Quick Ratio
TARS
Profitability
|
Metric
|
TARS
|
|---|---|
Return on Assets (Normalized) | −0.28% |
Return on Equity (Normalized) | −0.44% |
Return on Invested Capital (Normalized) | −2.25% |
Return on Assets
TARS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Pvzpxkhyl | Lmjbdv | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gqvzvmmh | Pngvmj | $63B | |||
| argenx SE ADR
ARGX
| Jcdnmsdm | Wjp | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qkbxxgg | Ztncsm | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Xnmwrcwd | Lywynk | $24B | |||
| BioNTech SE ADR
BNTX
| Jwdjqnkv | Hpz | $22B | |||
| Incyte Corp
INCY
| Nbpcdwx | Mgll | $21B | |||
| Moderna Inc
MRNA
| Qhymqzk | Bsjc | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Lqwyzmcwb | Ctlx | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Wbmxczgk | Fvjm | $13B |
United States